BACKGROUND: Pulmonary metastasectomy (PM) is a standard procedure in the treatment of stage IV colorectal cancer (CRC). In most centers the indication for PM is solely based on clinical factors without taking the tumor biology into account. This results in diverse outcomes ranging from long-term remission to early recurrence. Inflammation is considered a hallmark of cancer development and progression. On the other hand the accessibility of CRC cells to the immune system reflects the grade of tumor aggressiveness. We sought to investigate the impact of cyclooxygenase-2 (COX-2) and prostaglandin-E2 (PGE2) expression in pulmonary metastases on different outcome parameters following PM. METHODS: From 04/2009 to 11/2013 53 patients with complete PM for CRC were included in this single-center study. Tissue samples of resected pulmonary metastases and available corresponding primaries were collected and assessed by immunohistochemistry for COX-2 and PGE2 expression of the tumor tissue and the peritumoral stroma. Results were correlated with clinical outcome parameters. RESULTS: COX-2 and PGE2 were detected in nearly every pulmonary CRC metastasis. Staining intensities of pulmonary metastases correlated only weakly with intensities found in primary tumors. When dividing metastases in high expressing and low expressing tumors, a trend towards longer recurrence free survival and improved survival was found in tumors with strong COX-2 and PGE2 staining. CONCLUSIONS: In conclusion, this pilot study shows that COX-2 and PGE2 are uniformly overexpressed in pulmonary metastases from CRC. High expression of COX-2 and PGE2 seems to reflect a beneficial tumor biology with late tumor recurrence and prolonged overall survival after PM.
BACKGROUND: Pulmonary metastasectomy (PM) is a standard procedure in the treatment of stage IV colorectal cancer (CRC). In most centers the indication for PM is solely based on clinical factors without taking the tumor biology into account. This results in diverse outcomes ranging from long-term remission to early recurrence. Inflammation is considered a hallmark of cancer development and progression. On the other hand the accessibility of CRC cells to the immune system reflects the grade of tumor aggressiveness. We sought to investigate the impact of cyclooxygenase-2 (COX-2) and prostaglandin-E2 (PGE2) expression in pulmonary metastases on different outcome parameters following PM. METHODS: From 04/2009 to 11/2013 53 patients with complete PM for CRC were included in this single-center study. Tissue samples of resected pulmonary metastases and available corresponding primaries were collected and assessed by immunohistochemistry for COX-2 and PGE2 expression of the tumor tissue and the peritumoral stroma. Results were correlated with clinical outcome parameters. RESULTS:COX-2 and PGE2 were detected in nearly every pulmonary CRC metastasis. Staining intensities of pulmonary metastases correlated only weakly with intensities found in primary tumors. When dividing metastases in high expressing and low expressing tumors, a trend towards longer recurrence free survival and improved survival was found in tumors with strong COX-2 and PGE2 staining. CONCLUSIONS: In conclusion, this pilot study shows that COX-2 and PGE2 are uniformly overexpressed in pulmonary metastases from CRC. High expression of COX-2 and PGE2 seems to reflect a beneficial tumor biology with late tumor recurrence and prolonged overall survival after PM.
Authors: Mi Ri Hwang; Ji Won Park; Dae Yong Kim; Hee Jin Chang; Sun Young Kim; Hyo Seong Choi; Moon Soo Kim; Jae Ill Zo; Jae Hwan Oh Journal: Ann Thorac Surg Date: 2010-08 Impact factor: 4.330
Authors: Thomas Schweiger; Dagmar Kollmann; Christoph Nikolowsky; Denise Traxler; Emmanuella Guenova; György Lang; Peter Birner; Walter Klepetko; Hendrik Jan Ankersmit; Konrad Hoetzenecker Journal: Eur J Cardiothorac Surg Date: 2013-12-08 Impact factor: 4.191
Authors: H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla Journal: Cancer Res Date: 1995-09-01 Impact factor: 12.701
Authors: Thomas Schweiger; Veronika Starkl; Olaf Glueck; Christoph Glogner; Denise Traxler; Julia Jedamzik; Sandra Liebmann-Reindl; Peter Birner; Berthold Streubel; Walter Klepetko; Konrad Hoetzenecker Journal: Eur J Cardiothorac Surg Date: 2015-10-24 Impact factor: 4.191
Authors: Santiago Zelenay; Annemarthe G van der Veen; Jan P Böttcher; Kathryn J Snelgrove; Neil Rogers; Sophie E Acton; Probir Chakravarty; Maria Romina Girotti; Richard Marais; Sergio A Quezada; Erik Sahai; Caetano Reis e Sousa Journal: Cell Date: 2015-09-03 Impact factor: 41.582
Authors: Thomas Schweiger; Anna Sophie Berghoff; Christoph Glogner; Olaf Glueck; Orsolya Rajky; Denise Traxler; Peter Birner; Matthias Preusser; Walter Klepetko; Konrad Hoetzenecker Journal: Clin Exp Metastasis Date: 2016-07-23 Impact factor: 5.150
Authors: Thomas Schweiger; Sandra Liebmann-Reindl; Olaf Glueck; Patrick Starlinger; Johannes Laengle; Peter Birner; Walter Klepetko; Dietmar Pils; Berthold Streubel; Konrad Hoetzenecker Journal: J Thorac Dis Date: 2018-11 Impact factor: 2.895